Cargando…

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS

We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 allotranspla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chevallier, Patrice, Labopin, Myriam, de La Tour, Regis Peffault, Lioure, Bruno, Bulabois, Claude‐Eric, Huynh, Anne, Blaise, Didier, Turlure, Pascal, Daguindau, Etienne, Maillard, Natacha, Yakoub‐Agha, Ibrahim, Guillerm, Gaelle, Delage, Jeremy, Contentin, Nathalie, Bay, Jacques‐Olivier, Beckerich, Florence, Bourhis, Jean‐Henri, Detrait, Marie, Vigouroux, Stéphane, François, Sylvie, Legrand, Faezeh, Guillaume, Thierry, Mohty, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119961/ https://www.ncbi.nlm.nih.gov/pubmed/27748046 http://dx.doi.org/10.1002/cam4.880

Ejemplares similares

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC
por: Le Bourgeois, Amandine, et al.
Publicado: (2018)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia — an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Czerw, Tomasz, et al.
Publicado: (2016)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study
por: Mohty, Mohamad, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Use of clofarabine for acute childhood leukemia
por: Pession, A, et al.
Publicado: (2010)

Dual anti-HIV mechanism of clofarabine
por: Daly, Michele B., et al.
Publicado: (2016)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Treating refractory leukemias in childhood, role of clofarabine
por: Harned, Theresa M, et al.
Publicado: (2008)

Fludarabine-Based Low-Intensity Conditioning for Fanconi Anemia is Associated with Good Outcomes in Aplastic Anemia but not in MDS - a Single-Center Experience
por: Chattopadhyay, Sohini, et al.
Publicado: (2023)

P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY
por: Mohty, M., et al.
Publicado: (2022)

Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia
por: Karakaş, Zeynep, et al.
Publicado: (2014)

[(18)F] Clofarabine for PET Imaging of Hepatocellular Carcinoma
por: Sergeeva, Olga, et al.
Publicado: (2019)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Clofarabine desensitization: A case report: Leukemia research reports
por: Hayes, Sarah M., et al.
Publicado: (2017)

Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters
por: Miller, Siennah R., et al.
Publicado: (2021)

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
por: Irie, Masahiro, et al.
Publicado: (2021)

Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia
por: Jeha, Sima, et al.
Publicado: (2023)

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
por: Rubio, Marie Thérèse, et al.
Publicado: (2017)

Efficacy of Low Dose Clofarabine in Refractory Precursor T- Acute Lymphoblastic Leukemia
por: Choi, Jaehyuk, et al.
Publicado: (2007)

A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer
por: Khalafi, Shayan, et al.
Publicado: (2021)

Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients
por: Nijstad, A. Laura, et al.
Publicado: (2021)

Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS
por: Michel, Claire, et al.
Publicado: (2023)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
por: Giannotti, Federica, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
por: Chevallier, Patrice, et al.
Publicado: (2018)

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
por: Tse, Eric, et al.
Publicado: (2011)

French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
por: Trioche, Pascale, et al.
Publicado: (2012)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation
por: Lee, Yoon-Jin, et al.
Publicado: (2012)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqn11cv8i37cmalbcesbm4bp1r